Radiotherapy is a treatment method for cancers using ionizing radiation (IR). Radiotherapy-induced complications to normal tissues have been major drawbacks. One of the strategies for preventing or reducing these side effects is the use of natural radioprotectors such as melatonin. Melatonin is largely secreted in the pineal glands of mammals. Studies have evaluated its radioprotective effect mostly using animal models. However, in this review, we discuss the findings of various clinical studies that utilized melatonin in radiotherapy. Online databases (PubMed, Scopus, Embase, and Google Scholar) and ClinicalTrials.gov were searched to retrieve relevant clinical studies which utilized melatonin alongside radiotherapy. The literature reviewed showed that melatonin administration prevented radiation-induced dermatitis, delayed the onset of oral mucositis, and improved treatment outcomes as well as patients' quality of life after radiotherapy. These studies reported minimal toxicities from melatonin administration. However, their results were not in agreement in terms of patient survival. The application of melatonin in radiotherapy showed potentials for improving treatment outcomes as well as preventing or ameliorating radiotherapy-induced side effects. We recommend further clinical trials for more insights especially in areas such as optimal melatonin dose and patient survival.
Introduction
Radiotherapy, also known as radiation therapy, is the treatment of cancers using ionizing radiation (IR). The radiations interact with the DNA of cancer cells, thereby halting their ability to reproduce, leading to cancer cell death. It has been estimated that between 50 and 70% of cancer patients receive radiotherapy either alone or in combination with other treatment methods such as surgery, chemotherapy, and immunotherapy [1] . In the case whereby a cancer cannot be completely treated, radiation therapy can also be used to relieve pains as well as improve the quality of life of patients. This is known as palliative radiation therapy.
Radiotherapy aims to achieve the control of tumors while minimizing side effects to normal tissues. Novel radiotherapy methods such as intensity-modulated radiotherapy (IMRT), conformal radiotherapy, image-guided radiotherapy (IGRT), and stereotactic body radiotherapy (SBRT) limits the radiation doses to the irradiated volume, thereby sparing normal tissues during irradiation [2, 3] . Another approach-heavy particle radiation-makes use of the Bragg peak phenomenon in reducing dose delivered to healthy tissues [4] .
However, side effects have been reported in several studies [5] . These side effects could be early or late. Early effects such as skin reactions, apoptosis, lymphocyte adhesion and infiltration, vascular permeability, increased endothelial cell swelling, and edema occur within hours after radiation exposure [6] . However, late effects including necrosis, organ dysfunction, death, and secondary cancer may arise months to years after treatment [7] . With these in mind, advancements in radiotherapy are geared towards This article is part of the Topical Collection on Medicine * Ahmed Eleojo Musa musahmed@yahoo.com improving treatment efficacy while ensuring that patient safety in the short and long runs are not compromised. Studies have shown that radiation-induced toxicities to living systems are mostly as a result of the production of free radicals in cells by IR [8] . The mechanism as well as response to these toxicities varies for different organs [9, 10] . The need to neutralize these free radicals or repair damages induced by these free radicals forms the basis in the development of radioprotective agents (also known as radioprotectors). An ideal radioprotector should have minimal toxicities and protect normal tissues (especially radiosensitive organs such as gastrointestinal and hematopoietic) but not tumor cells [11] . In addition, availability and cost effectiveness are important factors to be considered [12] . The first FDA-approved radioprotective agent was amifostine. However, due to possible side effects to patients, its use has been discontinued [13] .
In recent times, natural substances such as selenium, rutin, co-enzyme q10, curcumin, resveratrol, quercetin, beta-carotene, α-tocopherol, caffeic acid, melatonin, and ascorbic acid have been explored for their radioprotection potentials. In this review, our focus will be on melatonin. Numerous studies, mostly in vitro and in vivo, have been conducted using melatonin as a radioprotector and radiosensitizer [14] . However, this review will be centered on the various clinical studies which made use of melatonin in radiotherapy.
Melatonin (N-acetyl-5-methoxytryptamine), a hormone majorly secreted in the pineal gland, was discovered in 1958 by Aaron Lerner [15] . It is involved in the circadian regulation of biological and endocrine functions such as mood, sleep, sexual progression and reproduction, immune activities, and aging [16] [17] [18] . Although, largely concentrated in the pineal gland of the brain, melatonin has also been observed in various organs and tissues such as the gastrointestinal tract (GIT) [19] [20] [21] and some leucocytes [22, 23] . In plants, melatonin can be found in cereals, olive, walnuts, tomatoes, pineapple, ginger, legumes, etc [24] . The concentration of melatonin in the body varies with time, with its peak secretion at night and lowest during the day [25] [26] [27] [28] [29] [30] . Its amount also reduces with increasing age [31] [32] [33] . Following its secretion in the pineal gland, it is released into the bloodstream to other body fluids such as saliva [34, 35] , semen [36] , bile [37] , cerebrospinal fluid [38] [39] [40] , and minute quantities in the urine [41] [42] [43] . The properties of melatonin which are of importance to radiotherapy are summarized below:
Antioxidant Effect
Melatonin has been found to possess potent antioxidant effect against IR [44] . Its antioxidant effect can either be direct or indirect. The former involves scavenging free radicals including reactive oxygen species (ROS) and reactive nitrogen species (RNS) while the latter is due to variations in gene transcription as well as the activities of antioxidants and ROS/NOproducing enzymes [45] [46] [47] . Biochemically, melatonin's antioxidant effect leads to an increase in the molecular amounts of superoxide dismutase (SOD) and glutathione peroxidase (GPx) as well as decrease in the levels of malondialdehyde (MDA), glutathione (GSH), and nitric oxide (NO) activity [48, 49] . Its antioxidant property plays a major role in the use of melatonin as a radioprotector. This has been observed in animal studies for various organs such as the lung, colon, ileum [50] , skin [51] , liver [50, [52] [53] [54] , lens [55, 56] , spleen [57] [58] [59] , brain [60] , and spinal cord [61, 62] .
Antiapoptotic Effect
Apoptosis, also known as programmed cell death, was discovered by Kerr et al. in 1972 [63] . It is a process in which the cells in the body die spontaneously. Exposure to IR has been shown to enhance this process, thereby occurring earlier (4-6 h after irradiation) than normal [64] . Furthermore, it was observed that after a radiotherapy dose of 2 Gy, a survival value of 53% for cells with apoptosis was obtained compared with 67% for cells without apoptosis [64] . Hence, apoptosis could negatively affect radiotherapy outcomes.
Animal studies have shown that via several mechanisms such as increasing Bcl-2 gene expression versus a significant decrease in Bax gene expression [65] , decrease in caspase-3 activity [59] , upregulation of bcl-2 as well as reduction of bax/bcl-2 ratio [66] , and relative decline in p53 expression [67] , melatonin protects against IRinduced apoptosis. Inhibition of COX-2, NF-κB, iNOS, and Sirt1, as well as TGF-β activation, has also been attributed to its antiapoptotic effect [67, 68] .
Anti-inflammatory Effect and Tumor Sensitization
The anti-inflammatory abilities of melatonin have been reported in several studies. Melatonin decreases the overexpression of Th1 cytokines involved in inflammation such as TNF-α, IL-1β, and IFN-γ, and increases Th2 response [69, 70] . Another study by Bondy et al. revealed that via impeding the release of TNF-α and IL-8, two major cytokines involved in chronic inflammation, melatonin could decrease acute and chronic inflammations following radiotherapy [71] . Furthermore, it modulates inflammation via decreasing necrosis as well as apoptosis induction, subdues toll like receptors (TLRs), hinders the secretion of prostaglandins via COX-2 inhibition, and lessens fibrosis by suppressing pro-fibrotic enzymes [72] .
Exposure to IR can lead to inflammation, which in turn gives rise to tumor resistance through the triggering of proangiogenesis factors such as COX-2, vascular endothelial growth factor (VEGF), as well as growing number of macrophages and T regulatory cells (Tregs) [73] . Melatonin has been shown to reduce tumor growth via inhibition of VEGF and other growth factors like endothelin-1, hypoxia-inducible factor-1α (HIF-1α), epidermal growth factor receptor (EGFR), and insulin-like growth factor 1 (IGF-1), thereby sensitizing tumor cells to radiotherapy [74] [75] [76] [77] [78] . In another study, pretreatment of MCF-7 human breast cancer cells with melatonin (1 mM, 10 μm, and 1 nM) 1 week before 8 Gy single dose X irradiation led to sensitization of human breast cancer cells to ionizing radiation via a 50% reduction in the activities as well as expressions of proteins involved in the synthesis of estrogens in these cells [79] . Furthermore, the p53 expression (which has a key role in tumor suppression) was significantly increased by twofold when the cells were pretreated with 1 nM melatonin compared with radiation alone (P < 0.001).
Anti-cancer Effect
Epidemiological studies have revealed an increase in the risk of cancer in persons with insufficient melatonin levels [80, 81] . A review by Li et al. highlighted the various epidemiological studies supporting the anti-cancer effect of melatonin for various cancer types including breast, prostate, ovarian, and solid tumors [82] . A meta-analysis of randomized controlled trials (RCTs) for solid tumors treated with radiochemotherapy as well as 20-mg melatonin administered orally showed that melatonin significantly enhanced complete and partial remission (16.5 vs. 32.6%; RR = 1.95, 95% CI 1.49-2.54; P < 0.00001), 1-year survival rate (28.4 vs. 52.2%; R R = 1 . 9 0 ; 9 5% C I 1 . 2 8 -2 . 8 3 ; P = 0 . 0 0 1 ) [ 8 3 ] . Experimental studies have attributed the anti-cancer effect of melatonin to its antiproliferative effect [84] , antiestrogenic effect via ERα-signaling pathway as well as inhibition of aromatase activity [85] [86] [87] , angiogenesis [77] , modulation of melatonin receptors [88] , induction of apoptosis [89] , and inhibition on invasion [90] .
The synergic effect of melatonin on cancer cells when administered with ionizing radiation has also been observed. In a study by Alonso-González et al., MCF-7 human breast cancer cells were pretreated with melatonin (1 mM, 10 μm, and 1 nM) 1 week before single dose (0-12 Gy) X irradiation. Their results showed that compared with radiation alone, pretreatment with melatonin led to a significant reduction in cell proliferation, inducing cell cycle arrest and downregulating proteins involved in double-strand DNA break repair [91] . These results were also confirmed in a further study [79] .
Findings from Clinical Studies which Made Use of Melatonin in Radiotherapy
So far, few clinical studies have been conducted to evaluate several applications of melatonin in radiotherapy. Table 1 gives the summaries of findings from these studies. The first clinical study was conducted by Lissoni et al. to evaluate the effect of melatonin combination with radiotherapy on the survival of glioblastoma patients. Their results showed significant improvement in the 1-year survival of radiotherapy patients treated with melatonin compared with radiotherapy alone (6/14 vs. 1/16, P < 0.02). Although, they were unable to explain the mechanism of prolonged survival by melatonin, they suggested that its ability to counter tumor resistance to radiotherapy-induced apoptosis could play a role [98] .
Interestingly, a later study by the Radiation Therapy Oncology Group (RTOG) disproved the survival efficacy of melatonin combination with radiotherapy. A total of 126 RTOG RPA class 2 patients with brain metastases were randomized to receive same oral melatonin dose (20 mg) as that of the previous study. Furthermore, patients received radiotherapy at 30 Gy in 10 fractions. A total of 118 patients died, with results showing a median survival of 3.4 and 2.8 months for patients administered melatonin in the morning and evening, respectively. However, the control arm (without melatonin) had a median survival of 4.1 months. Hence, there was no significant improvement in survival. They were unable to explain the disparities in the outcomes from these studies [97] .
Lymphocytopenia, a medical condition in which the lymphocytes (a kind of white blood cell) in the bloodstream fall below normal levels, is one of the complications arising from radiotherapy. Due to the key role of lymphocytes in suppressing anticancer immunity, lymphocytopenia negatively affects treatment outcomes of radiotherapy. Studies have found association between radiotherapy-induced lymphocytopenia and several cancers [99] [100] [101] [102] . In a bid to counter radiotherapyinduced lymphocytopenia, a study by Lissoni and colleagues evaluated the potentials of melatonin (20 mg), 5 methoxytriptamine (5-MTT) as well as low-dose IL-2 (a lymphocyte growth factor). Twenty rectal cancer or uterine cervix carcinoma patients were pelvic irradiated with a total dose of 50.4 Gy in addition to treatments with each of the different interventions. Their results showed that melatonin nor its combination with 5-MTT was able to significantly protect against lymphocytopenia, while IL-2 reduced this effect but not completely [96] . They suggested a higher melatonin dosage (> 30 times study dose) for improved outcomes according to previous findings [103] .
The largest organ in the body, the skin, is the first organ of contact during radiotherapy. It has been shown that the bone marrow and skin epithelium are easily susceptible to radiationinduced damages [104] . Radiotherapy-induced complications to the skin are collectively known as radiodermatitis. It is commonly observed after radiotherapy for breast cancer. Acute radiodermatitis with symptoms such as erythema, erosion, scaling, ulcer, and edema may occur within a period of 90 days following radiotherapy. On the other hand, chronic radiodermatitis with signs including hypopigmentation or hyperpigmentation, telangiectasis, variations in skin texture, poikiloderma, and orange peel may arise 6 months to years after radiotherapy. The effect of melatonin in preventing radiation dermatitis has been evaluated. In a phase 2, prospective, double-blind randomized trial, 47 female breast cancer patients received a total radiation dose of 50 Gy as well as topical melatonin to their irradiated breasts. Results showed a significant reduction in the incidence of radiation dermatitis in the melatonin-treated group compared with placebo (without melatonin) (59% vs. 90%, P = 0.038) [95] . Similar results were obtained in a recent study by Ana C. Fernández-Tresguerres [93] involving 25 patients (23 breast cancer, 1 lung cancer, and 1 lymphoma) who received between 14 and 26 radiotherapy sessions as well as topical application of melatonin to the treated areas. Furthermore, it was suggested that topical administration of melatonin could be better compared with its oral form. In oral administration, melatonin is absorbed in the lower blood levels, hence not enough amount of melatonin gets to the skin [105] . However, when applied topically, melatonin easily penetrates the skin's outer later, known as stratum corneum [106] . We observed that the doses of melatonin applied in both studies were not mentioned.
Mucositis is one of the severe side effects to head and neck cancer patients receiving chemo and/or radiotherapy [107] [108] [109] . Its dose-limiting effect reduces patient survival [110] , gives rise to infections [111, 112] , and negatively affects patients' quality of life [113] . The efficacy of melatonin as an adjuvant has been assessed in recent studies. In a study involving 39 head and neck cancer patients receiving concurrent chemoradiation as well as 20-mg melatonin capsules, the appearance of grade 3 oral mucositis was significantly delayed compared with placebo (median 34 days vs. 50 days; P = 0.0318). This facilitated uninterrupted treatment, thereby improving treatment outcomes [94] . Similar results were observed in another study by Lozano et al. involving a higher patient population. Moreover, improved outcomes were obtained when melatonin was used in addition with cisplatin [92] .
Checks on the website www.ClinicalTrials.gov have revealed ongoing clinical trials involving melatonin's use in combination with radiotherapy. Table 2 presents a summary of the characteristics of these studies.
Effect of Melatonin Administration on Patients' Quality of Life After Radiotherapy
In all concluded clinical studies, minimal toxicities were observed. Studies have revealed the effect of radiotherapy in the depletion of pituitary hormones [114] [115] [116] . However, Lissoni et al. reported improvement in sleep and dream, as well as a significant reduction in infection for brain glioblastoma patients who received melatonin with radiotherapy compared with radiotherapy alone (2/14 vs. 8/16, P < 0.025) [98] . Melatonin has also been shown to be useful for treating insomnia after radiotherapy. In this study, a patient with anaplastic glioma received conformal radiation therapy with 2 Gy/ fraction up to 60 Gy. The patient reported lack of sleep at the end of radiotherapy. Following administration of 3-mg melatonin capsule, the patient experienced better sleep [117] .
Toxicities such as fatigue, rash, and neurological changes were observed by Berk et al.; however, they were well tolerated [97] . Onseng et al. showed that melatonin administration brought about a significant reduction in the need for pain control compared with control (P = 0.034) [94] .
Conclusion
Advantages of melatonin as a therapeutic agent such as low toxicity and ease of penetration in different cell types make it suitable for use in clinical radiotherapy. Furthermore, melatonin administration before irradiation can serve as a potent radioprotector due to its antioxidant effect and rapid absorption in different organs. Through the stimulation of DNA repair enzymes in damaged cells, melatonin reduces cell death, improves tissue tolerability, and prevents initiation of several signaling pathways which lead to chronic inflammation and redox reactions. Early and late side effects of radiotherapy including myelopathy, fibrosis, mucositis, dermatitis, and pneumonitis are also prevented via targeting several inflammatory agents. Lastly, its radiosensitize effect aids dose [97] . The absorption of melatonin also varies between individuals [118] . Another drawback is the variation in melatonin concentration at different times with its peak at night and low levels during the day.
In summary, this review has discussed the various clinical applications of melatonin in radiotherapy, with our findings showing that melatonin administration prevented radiation-induced dermatitis. Furthermore, as a promising adjuvant for concurrent chemoradiation in patients with head and neck cancer, it delayed the onset of oral mucositis, leading to uninterrupted treatment and improvement in treatment outcomes. Side effects due to melatonin administration were minimal and even non-existent in some studies, hence, dispelling any safety concerns to humans. The administration of melatonin after radiotherapy was shown to improve patients' quality of life including better sleep and a reduction in anxiety.
The effect of melatonin on patient survival was not confirmed as studies differed on this aspect. In addition, melatonin administration could not prevent radiotherapyinduced lymphocytopenia. It was suggested that a higher dose may prove effective. In terms of dosage, the most effective dose for human is still not clear even though in most of the reported studies, 20-mg melatonin was used. Moreover, there was no strict monitoring of patients to ensure that they were taking melatonin at the appropriate time. Studies also varied in terms of different periods between melatonin administration and irradiation. Furthermore, the reviewed clinical studies did not recruit a large number of patients, with most of the studies involving less than 50 patients. Nevertheless, based on results from these studies, we conclude that melatonin may be efficient in improving treatment outcomes of radiotherapy, while decreasing side effects to normal tissues. However, more clinical trials with large number of patients are still required for further insights into areas such as optimal melatonin dose and time-lapse between administration and irradiation as well as its effects on patient survival rates after radiotherapy. The molecular and cellular mechanism of these effects should also be further investigated for clarity.
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